Clinical Observation of Treating Infantile Ophthalmic Hemangioma by Oral Propranolol
International Journal of Ophthalmology & Visual Science
Volume 4, Issue 4, December 2019, Pages: 97-100
Received: Oct. 1, 2019;
Accepted: Oct. 21, 2019;
Published: Nov. 19, 2019
Views 343 Downloads 90
Jing Huang, Guangzhou Women and Children’s Medical Center, Guangzhou, China
Daoman Xiang, Guangzhou Women and Children’s Medical Center, Guangzhou, China
Follow on us
To evaluate the clinical efficacy and safety by oral propranolol in treating infantile ophthalmichemangioma (IH). A prospective analysis of 66 infantile outpatients with ophthalmic hemangioma from Feb 2016 to Apr 2018. According to the initial dose, the order of maintenance dose and drug withdrawal of oral propranolol prescription, the tumor size, color change and adverse reactions were studied and analyzed, and the clinical efficacy and safety were evaluated. The tumors became weak within 1 week in 83.3% outpatients (55 cases). 4 (6.1%) outpatients received Grade I efficacy (ineffective), 7 (10.6%) Grade II (poor), 9 (13.6%) Grade III (improvement) and 46 (69.7%) Grade IV (cured). The average prescribed medication treatment time was 6.9 months. The curative effect of the long course groups was better than the short ones, and 4-12 months group was the best. No obvious side effect was detected except 1 diarrhea. There was no significant difference in curative effect between left and right eyes or sex (P>0.05). Propranolol was used in outpatients to treat IH, the indications and contraindications were strictly controlled and the clinical efficacy and safety were relatively satisfactory.
Propranolol, Infantile, Eye, Hemangioma, Angioma
To cite this article
Clinical Observation of Treating Infantile Ophthalmic Hemangioma by Oral Propranolol, International Journal of Ophthalmology & Visual Science.
Vol. 4, No. 4,
2019, pp. 97-100.
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fengming Li. Chinese Ophthalmology. Version 2. Beijing: People's Health Press, 2005.
Haider K, Plager DA, Neely DE, et al. 0utpatient treatment of periocular infantile hemhemangiomas with oral propranlolo. J AAPOS. 2010, 14: 251-256.
Daoman Xiang, Hongmei Zhou, Guangqiang Feng, et al. Chinese Journal of Medical Aesthetics and Cosmetology. 2006, 12 (2): 71-73.
Przewratil P, Sitkiewicz A, Wyka K, et al. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in children with hemhemangiomas and vascular malformations preliminary report. Pediatr Dematol, 2009, 26: 399-404.
Przewratil P, Sitkiewicz A, Andrzeijwska E. Local serum levels of vascular endothelial growth factor in infantile hemhemangioma: intriguing mechanisms of endothelial growth. Cytokine, 2010, 49: 141-147.
Ming Zhang, Qiang Peng, Ming Liu. Expression of NF-kappa B in propranolol treatment for infantile hemangioma in nude mice model. Journal of Clinical Pediatric Surgery. 2019, 18 (8): 655-659.
Holmes WJ, Mishra A, Gorst C, et al. Propranolol as first-line treatment for rapidly proliferating Infantile Haemhemangiomas. J Plast Reconstr Aesthet Surg, 2011, 64: 445-451.
Tingting Lin, Yanjin He. The advance of β-blockers in the treatment of infantile hemangiomas. Chinese Journal of Ophthalmology. 2013, 49 (12): 1138-1144.
Lu Yu, Li Li, Lin Ma. Short-and long-term safety of oral propranolol in the treatment of infantile hemangioma.
Chinese Journal of Dermatology. 2019, 52 (8): 586-589.
Jianmei Huang, Wenying Liu. A literature review of treating infantile hemangiomas with propranolol. Chinese Journal of Pediatric Surgery. 2018, 39 (2): 150-154.
Yanhui Cui, Qian Wu, Dayong Bai, et al. Clinical observation for treating children eyelid periorbital hemangioma by oral propranolol. Chinese Journal of Strabismus & Pediatric Ophthalmology. 2015, 23 (1): 18-23.
The Chinese version of this article was published in the journal of clinical ophthalmology in June 2019.